ArticleBiological trace element research2025
Serum Cadmium and Lead Levels in Thalassemic Patients of Najaf Governorate, Iraq.
Article in Biological trace element research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Thematological is a class of hereditary hematologic illnesses resulting from abnormalities in the production of one or more hemoglobin chains. Patients with β-Thematological may have a reduction in heavy metal levels as a result of iron chelate medication. The aim is to study the levels of heavy metals (toxic) in the blood of beta-Thematological patients and compare them to healthy people for the purpose of arriving at indicators through which it is possible to assist in early diagnosis of this disease or reduce symptoms. The study included 80 patients in comparison with age- and gender-matched 40 healthy individuals as controls. Samples were gathered between July 1, 2023, and September 1, 2023. The patients were interviewed for socio-demographic variables, and their medical histories were obtained from the hospital files. Cadmium and lead concentrations were determined using flame atomic absorption spectrometry (FAAS). All samples from Thematological patients were taken after the chelating therapy. Cadmium levels in Thematological patients were found to be lower in both genders in the control group. Lead levels were found to be greater in male Thematological patients and lower in female Thematological patients than those in the control group of female Thematological patients. Additionally, it was observed that patients from areas outside of Najaf's city center had greater levels of lead and cadmium than patients from the city center. Cadmium and lead levels in the serum were often low in Thematological patients. Heavy metals are eliminated when deferasirox chelate is taken.
Indexed as
Identifiers
38720019What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.